DOWN TO 6 YEARS OLD
FOR MILD TO MODERATE ATOPIC DERMATITIS
ZORYVE® ITRELIEVE ITANYWHERE
ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use.1Symptoms illustrated. Not an actual patient.
ZORYVE treats it, wherever patients need it, with an easy, once-daily, steroid-free topical1
ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use.1
SIMPLIFY ATOPIC DERMATITIS RELIEF WITH ZORYVE (zor-EEV)
31% of patients achieved vIGA-AD Success at Week 4, some as early as Week 1.2,3
32% of patients achieved WI-NRS Success at Week 4, with results observed within 24 hours.3
vIGA-AD Success = Achievement of Clear/Almost Clear and a ≥2-grade improvement from baseline. vIGA-AD = Validated Investigator Global Assessment—Atopic Dermatitis.
WI-NRS Success defined as a ≥4-point improvement for patients with a baseline score ≥4. WI-NRS scale: 0 (no itch) to 10 (worst imaginable itch). WI-NRS = Worst Itch Numeric Rating Scale.
ZORYVE CREAM.
ONCE A DAY.
ANYWHERE.
Reliable results anywhere on the body with a once-daily, steroid-free topical (down to 6 years old)1
See before and after photos
Committed to affordable patient access across all indications
One ZORYVE Direct Savings Program helps eligible, commercially insured patients get access and start ZORYVE treatment quickly and easily*†
Learn about patient
access support
*Prescriptions will be delivered to the patient 1–2 days after processing.
†Subject to eligibility criteria and maximum program limitation. This offer is not valid for patients without commercial drug insurance or whose prescription claims are eligible to be reimbursed, in whole or in part, by any government program. Please see Terms and Conditions.